AllianceBernstein’s Tonix Pharmaceuticals TNXP Stock Holding History

AllianceBernstein’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Buy	24,030 +10,960	+84%	+$141K	﹤0.01%	2935
2026 Q1	$204K	Hold	13,070	–	–	﹤0.01%	3043
2025 Q4	$204K	Hold	13,070	–	–	﹤0.01%	3060
2025 Q3	$316K	Hold	13,070	–	–	﹤0.01%	2920
2025 Q2	$470K	Buy	+13,070	New	+$342K	﹤0.01%	2676
2022 Q2	–	Hold	0	–	-$23K	–	3376
2022 Q1	–	Hold	0	–	–	–	3213
2021 Q4	–	Hold	0	–	–	–	3222
2021 Q3	–	Hold	0	–	–	–	3165
2021 Q2	–	Hold	0	–	–	–	3123

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein's TNXP Position: Q2 2026 in Review

AllianceBernstein increased its Tonix Pharmaceuticals (TNXP) stake by 84% in Q2 2026, buying an estimated $141K and bringing the position to 24,030 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #2935.

AllianceBernstein first reported a position in TNXP in Q2 2025 and has held it in 5 quarters since. The position peaked at $470K in Q2 2025. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

AllianceBernstein held 24,030 shares of Tonix Pharmaceuticals worth $330K as of Q2 2026.
AllianceBernstein bought 10,960 Tonix Pharmaceuticals shares in Q2 2026, an estimated $141K.
Tonix Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2935 holding.
AllianceBernstein first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
AllianceBernstein's Tonix Pharmaceuticals position peaked at $470K in Q2 2025.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.